Unknown

Dataset Information

0

Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance.


ABSTRACT: Despite significant improvements in prognosis, a subset of patients with primary central nervous system lymphoma (PCNSL) remains at high risk for relapse. The treatment of relapsed and refractory (R/R) PCNSL remains a major clinical challenge. Herein, we present a 24-year-old patient with PCNSL who relapsed 4 years after initial diagnosis and subsequently became refractory to high-dose methotrexate (HD-MTX), temozolomide, whole brain radiation therapy (WBRT), ibrutinib, and lenalidomide. She received thiotepa with anti-programmed cell death protein 1 (PD-1) antibody and achieved partial remission and then underwent autologous stem cell transplantation (ASCT) with thiotepa-based conditioning. Post-transplant maintenance with thiotepa and anti-PD-1 at 3-month intervals resulted in a durable complete response (CR) in this case of R/R PCNSL. Our report highlights the important role of thiotepa in the treatment of patients with R/R PCNSL.

SUBMITTER: Wang L 

PROVIDER: S-EPMC10859448 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance.

Wang Luyao L   Fan Yili Y   Chen Boxiao B   Zhang Jiawei J   Yang Luyu L   Qiu Xi X   Jiang Huawei H   Li Jinfan J   Xiao Xibin X   Huang Liansheng L   Xu Yang Y  

Frontiers in oncology 20240129


Despite significant improvements in prognosis, a subset of patients with primary central nervous system lymphoma (PCNSL) remains at high risk for relapse. The treatment of relapsed and refractory (R/R) PCNSL remains a major clinical challenge. Herein, we present a 24-year-old patient with PCNSL who relapsed 4 years after initial diagnosis and subsequently became refractory to high-dose methotrexate (HD-MTX), temozolomide, whole brain radiation therapy (WBRT), ibrutinib, and lenalidomide. She rec  ...[more]

Similar Datasets

| S-EPMC8212249 | biostudies-literature
| S-EPMC3267827 | biostudies-literature
| S-EPMC10338202 | biostudies-literature
| S-EPMC6777912 | biostudies-literature
| S-EPMC11471030 | biostudies-literature
| S-EPMC6163063 | biostudies-literature
| S-EPMC9944873 | biostudies-literature
| S-EPMC5889038 | biostudies-literature
| S-EPMC7990745 | biostudies-literature
| S-EPMC7993097 | biostudies-literature